Topic: APPNLGF

Immunotherapy has shown promise in improving cognitive impairments in Alzheimer’s disease (AD) patients. However, further research is needed to explore target optimization and enhance the effective delivery of antibodies into the brain parenchyma. In this study, we aimed to explore methods for enhancing the efficiency of antibody entry into the brain parenchyma via cisterna magna injection to reduce plaque formation and decrease the levels of Aβ42 within hippocampal neurons. We employed intraperitoneal injection of 1M hypertonic saline to augment the delivery of antibodies in the cerebrospinal

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of β-amyloid plaques and Tau-containing neurofibrillary tangles, with no effective treatment currently available. To address the complex nature of AD pathology, we investigate a "multiple drugs – multiple targets" approach leveraging miRNA-based therapeutics. miRNAs, short non-coding RNAs, offer unique potential for gene network-based therapies due to their ability to regulate multiple genes within common biological pathways. Dysregulated miR-124 and miR-132, implicated in AD pathology, prese